98 results
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
16 Oct 15
Regulation FD Disclosure
12:00am
novel unprecedented targets
Tackling tough chemistry with allosteric inhibitors and activators Requiring a predictive marker prior to development … )
Novel First-in-Class Research Portfolio
Target Validation Compound Optimization
Target C
Two Cancer Metabolism
Multiple Other Oncology Targets
Wave
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
13 Jan 14
Regulation FD Disclosure
12:00am
studies
Early 2014
FIH studies
Mid-2014
ex-US Rts
US Rts
Inborn Errors of
Metabolism
Multiple Novel
Targets
Research Programs:
PKD …
Expansion
Cohorts
Late 2014
1,000 –
3,000 (U.S.)
New
Targets
Validated
Program
Development
Candidate
Phase 1
Multiple Ascending Dose Study
Agios
8-K
EX-99.2
AGIO
Agios Pharmaceuticals Inc
4 May 18
Results of Operations and Financial Condition
7:07am
Target Metabolic and Non-Metabolic Targets Celgene Collaboration MAT2A Follow-Ons Heme Lineage: AG-636 DHODH Genetically Defined Heme Target Genetically … ) Erythroid Porphyria Friedreich’s Ataxia Other Exploratory Programs T-cell and Tumor Target Macrophage Target Macrophage Target Tumor Target Other Targets (T
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
15 Oct 14
Regulation FD Disclosure
12:00am
Disorders of
Metabolism
(Multiple Novel Targets)
(Multiple Monogenic Diseases)
US Rts ex-US Rts
Phase 1
Studies
Hematologic Malignancies
Solid Tumors …
100’s of novel targets
Genetic-
or metabolic-biomarker defined patients
Rare Genetic Disorders of Metabolism
Agios Core
Capabilities
8-K
EX-99.2
AGIO
Agios Pharmaceuticals Inc
8 Dec 14
Agios Announces New Data from Ongoing Phase 1 Trial of AG-221 Showing Robust Clinical Activity in Patients with Advanced Hematologic Malignancies
12:00am
Exhibit 99.2
Agios Reports Positive Phase 1 Data in Healthy Volunteers for AG-348, a First-in-Class Investigational Medicine That Targets … was well tolerated. Since AG-348 targets both the mutant and wild-type PKR enzyme, the pharmacodynamic effect we observed provides evidence to support
8-K
EX-99.2
rwnmn75 4zpps
16 Oct 15
Regulation FD Disclosure
12:00am
424B4
vfax0jywh7
24 Apr 14
Prospectus supplement with pricing info
12:00am
8-K
EX-99.1
0f2bz8vilgv7d5qj9qjo
7 Aug 14
Agios Pharmaceuticals Reports Second Quarter 2014 Financial Results
12:00am
8-K
EX-99.1
ctgi to76h544b
13 Jun 14
Agios Pharmaceuticals Announces that Celgene Exercised its Option to License AG-221
12:00am
S-1
EX-10.13
dundz
10 Jun 13
IPO registration
12:00am
8-K
EX-99.1
fw1gcsz6 n9jis8297
7 Apr 14
Other Events
12:00am
8-K
EX-99.1
qj8zx1uczs 42mvej0
19 Nov 14
Agios Pharmaceuticals Announces Early Phase 1 Data Showing Clinical Activity of AG-120
12:00am
8-K
EX-99.1
pt48xbvy919g os0ren
16 Jun 14
Other Events
12:00am
424B4
cgm8x99ymbll38cs 53v
24 Jul 13
Prospectus supplement with pricing info
12:00am
8-K
31wv4nmvqx9
19 Nov 14
Agios Pharmaceuticals Announces Early Phase 1 Data Showing Clinical Activity of AG-120
12:00am
10-K
0e6qbtttb5 0c
18 Mar 14
Annual report
12:00am
8-K
ad909oyfj5eae 0p
28 Oct 19
Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study ofAG-270, a MAT2A Inhibitor, in Patients withMTAP-Deleted Tumors
7:20am